Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
INSM
INSM
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
INSM News
US Stocks Close Lower Amid Cautious Market Sentiment
4d ago
NASDAQ.COM
Insmed Q1 2026 Earnings Call Highlights
4d ago
seekingalpha
U.S. Stock Market Retreats as Oil Prices Surge
4d ago
NASDAQ.COM
US Stocks Show Mixed Movement, Tech Stocks Surge
4d ago
NASDAQ.COM
Mixed US Stock Indices with Nasdaq 100 Reaching All-Time High
4d ago
NASDAQ.COM
Insmed Launches Educational Initiative for Bronchiectasis Awareness
5d ago
PRnewswire
Insmed Partners with Ty Pennington to Raise Awareness of Bronchiectasis
5d ago
Newsfilter
Insmed to Announce Q1 Earnings on May 7th
5d ago
seekingalpha
Insmed Presents New Data Supporting BRINSUPRI® Impact on Respiratory Symptoms
May 04 2026
PRnewswire
Insmed Halts Lung Disorder Therapy R&D Program After Trial Failure
Apr 08 2026
seekingalpha
Insmed Halts Brinsupri Development for HS After Trial Failure
Apr 08 2026
Yahoo Finance
Insmed Discontinues Brensocatib Development After Phase 2b Study Fails
Apr 08 2026
NASDAQ.COM
Insmed Discontinues Brensocatib HS Program After Phase 2b Study Fails
Apr 07 2026
PRnewswire
Insmed's Investigational Treatment for Skin Disease Falls Short in Clinical Trial
Apr 07 2026
stocktwits
INSMED INC - PHASE 2B CEDAR STUDY OF BRENSOCATIB FAILED TO ACHIEVE EFFICACY GOALS
Apr 07 2026
moomoo
INSMED INC REPORTS NO NEW SAFETY CONCERNS FOR BRENSOCATIB IN PHASE 2B CEDAR TRIAL
Apr 07 2026
moomoo
Show More News
